PTO/SB/08s (08-03)
Approved for use through 97/31/2006, 0NE 0851-0231
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE
to a collection of information unless it contains a valid OMB control number.

	Application Number	- 1	10/10/9/	
	Filing Date		2003-11-24	
NFORMATION DISCLOSURE STATEMENT BY APPLICANT	First Named Inventor Hirohisa Yamada		isa Yamada	
Not for submission under 37 CFR 1.99)	Art Unit		2863	
not for submission under or or it may	Examiner Name	T. Lau	u	
	Attorney Docket Number	r	36856.1174	

				U.S.	PATENTS			Remove		
Examiner Ci Initial* N		Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document		Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear			ant
	1									
	2									
If you wis	to a	dd additional U.S. Pate	nt citatio	n information of	pase click the	Add button		Add		_
				ATENT APPLI				Remove		
Initial*	No 1	Publication Number	Code ¹	Date	of cited Doc	ument	Figure	ant Passages s Appear		
If you wisl	n to a	dd additional U.S. Pub	ished Ap	plication citation	n information	please click the Ad	d button			
If you wis	n to a	dd additional U.S. Pub	ished Ap	plication citation				Remove		
If you wisi Examiner Initial*		od additional U.S. Pub Foreign Document Number ³	Countr Code ²	FOREIGN PAT	Publication		e or		ant Relevant	76
Examiner	Cite	Foreign Document	Countr	FOREIGN PAT	Publication	Name of Patente	e or	Pages,Colum where Releva Passages or	ant Relevant	76

				NON-PAT	ENT LITERA	TURE DOCUM	ENTS	Remove	
Examiner Initials*	Cite No	(book, r		, serial, syn	mposium, cat		rticle (when appropriate pages (s), volume-is	iate), title of the item sue number(s),	Тъ
	1		Communication issues the communication issues (communication issues communication is communication in communication is communication is communication is communication in co	ued in corres	sponding Chin	ese Application N	o. 200310118060.5.		V
If you wish	n to a	d addition	onal non-patent lit	terature doc	cument citatio	on information p	lease click the Add t	outton Add	
				E	EXAMINER S	GNATURE			
Examiner	Signa	ture					Date Considered		_

See Kind Codes of USPTO Patent Documents at <u>www.USPTO.GDV</u> or MPEP 901.04. Fairler office that issued the document, by the two-letter code (WIPO Standard ST 3). *To: <u>Appeared point documents</u>, the indication of the year of the eight of the Emperor must precise the senial number of the patent document.

Figure 10 to 10 to

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10718797		
Filing Date		2003-11-24		
First Named Inventor Hiroh		isa Yamada		
Art Unit		2863		
Examiner Name T. La		u		
Attorney Docket Number		36856.1174		

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s);

That each item of information contained in the information disclosure statement was first cited in any communication of forms foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 3.7 CFR 197(eVI).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 156(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 157(c) for the filing of the information disclosure statement. See 37 CFR 157(c) for the filing of the information disclosure statement. See 37 CFR 157(c) for the filing of the information disclosure statement. See 37 CFR 157(c) for the filing of the information disclosure statement. See 37 CFR 157(c) for the filing of the information disclosure statement.

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- ☐ None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

_			
Signature	/Peter Medley #56,125/	Date (YYYY-MM-DD)	2006-05-05
Name/Print	Peter Medley	Registration Number	56125

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life and by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C.12 and 3T CFR.

1.14. This collection is estimated to take I hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, u.S. Operatment of Commence, P. O. Box 1430, Alexandriu, V.S. 2213.1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.A. 2213.1450.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that (1) the general authority for the collection of this information is \$3 U.S.C. 2(b)(2); (2) famishing of the information solicided is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kollie is to process and/or examine your submission related to a patient application or patient. If you do not furnish the requested process and/or examine your submission related to a patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested to the patient process and/or examine your submission, which may related that the patient process and/or examine your submission, which may

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, pursuant to 5 U.S.C. 552a(m.).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2504 and 2506. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make relevant for the state of the s
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 12(b) or issuance of a patient pursuant to 35 U.S. C. 15.1 Further, a record may be disclosed, subject to the limitations of 37 CFR.114, as a routine use, to the public if the record via flori of mapplication which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inseptions or an issued patient.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.